DentalEZ Alabama, Inc.
$5.9K 13 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ReShape Lifesciences Inc.
ReShape Lifesciences Inc. reported $5,842.88 across General Payments, Research, and Ownership to 15 physicians and teaching hospitals across 15 transactions.
- $5.8K Below-median payer
- All-tracks total
- 15 Below-median volume
- Transactions
- 15 Below-median reach
- Recipients
- −$34.2K
- General Payments vs PY2023
ReShape Lifesciences Inc. reported $5,842.88 across all CMS Open Payments tracks (General + Research + Ownership) to 15 physicians and teaching hospitals in Program Year 2024 - ranking #1698 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,842.88, averaging $389.53 per recipient.
ReShape Lifesciences Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer reshape-lifesciences-inc ReShape Lifesciences Inc.
$5.8K · #1698/1,925 · 0.0% industry · PY2024
- TOT $5.8K
- RANK #1698
- SHARE 0.0%
- TXN 15
- RCP 15
- CAT 2
- GEN $5.8K
- ΔGEN −$34.2K
- TOP1 73.4%
- PY 2024
Volume peers
Nearest volume peer: DentalEZ Alabama, Inc. ($5.9K)
ReShape Lifesciences Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ReShape Lifesciences Inc.'s CMS-reported General Payments decreased by $34.2K (−85.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: RESHAPE LIFESCIENCES INC.PY2023: RESHAPE LIFESCIENCES INC.PY2024: ReShape Lifesciences Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $40,057.06
- PY2024
- $5,842.88
What the Data Shows for ReShape Lifesciences Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For ReShape Lifesciences Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 2-category general-payment breakdown below at $5.6K (95.8% of General Payments, 5 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads ReShape Lifesciences Inc.'s 2-category general-payment breakdown at $5.6K, 95.8% of the reported total.
How ReShape Lifesciences Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $5.6K | 5 | 95.8% |
| Food and Beverage | $242.88 | 10 | 4.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $5,701.74 (97.6%) of $5,842.88 in this company's General Payments records across 12 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ReShape Lifesciences Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Christine Fielding
$4,287.50 across 4 reported transactions
- 2
Vafa Shayani
$1,312.50 across 1 reported transactions
- 3
Jeffrey Allen
$39.80 across 1 reported transactions
- 4
Jeffrey Holloway
$30.97 across 1 reported transactions
- 5
Amber Schulze
$30.97 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
ReShape Lifesciences Inc. ranks #1698 of 1,925 by total payments (bottom 12% by spend) but is notably more concentrated than that alone would suggest -- #270 of 1,838 by HHI (top 15% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- AmerisourceBergen Drug Corporation : $268.97 total payments, HHI 6066
- pharmaand GmbH : $12.7K total payments, HHI 5994
- Viseon, Inc. : $146.3K total payments, HHI 5966
- Digital Diagnostics Inc. : $54.4K total payments, HHI 5924
- Vertical Orthopaedics, Inc. : $34.2K total payments, HHI 5923
- TheraMicro, Inc. : $14.0K total payments, HHI 5918
- ReShape Lifesciences Inc. (this company) : $5.8K total payments, HHI 5891
- Rebiotix Inc. : $114.1K total payments, HHI 5889
- Spark Therapeutics, Inc. : $1.1M total payments, HHI 5876
- Agile Devices, Inc. : $8.4K total payments, HHI 5847
- Hubly Incorporated : $205.53 total payments, HHI 5839
- New York Blood Center, Inc. : $184.6K total payments, HHI 5838
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ReShape Lifesciences Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ReShape Lifesciences Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ReShape Lifesciences Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Perfuze Inc
$5.8K 5 recipients
Compare payment profiles
Escala Medical Inc.
$6.0K 52 recipients
Compare payment profiles
Dunamis Medical, LLC
$6.0K 48 recipients
Compare payment profiles
Bridge to Life Ltd
$5.6K 9 recipients
Compare payment profiles
Rare Disease Therapeutics, Inc.
$5.6K 104 recipients
Compare payment profiles
Put this to use
ReShape Lifesciences Inc. ranks #1698 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just ReShape Lifesciences Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.